69 related articles for article (PubMed ID: 26585134)
21. Heterogeneity of binding sites for tamoxifen and tamoxifen derivatives in estrogen target and nontarget fetal organs of guinea pig.
Gulino A; Pasqualini JR
Cancer Res; 1982 May; 42(5):1913-21. PubMed ID: 7066903
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Oesterreich S; Zhang Q; Hopp T; Fuqua SA; Michaelis M; Zhao HH; Davie JR; Osborne CK; Lee AV
Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
[TBL] [Abstract][Full Text] [Related]
23. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
24. Activation and immunorecognition by a monoclonal antibody of the tamoxifen-estrogen receptor complex.
Giambiagi N; Pasqualini JR
Biochim Biophys Acta; 1986 Oct; 883(3):559-66. PubMed ID: 3756221
[TBL] [Abstract][Full Text] [Related]
25. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
26. Estradiol and tamoxifen interaction at receptor sites at 37 C.
Fishman JH
Endocrinology; 1983 Sep; 113(3):1164-6. PubMed ID: 6191968
[TBL] [Abstract][Full Text] [Related]
27. Localization of the estrogen receptor in uterine cells by affinity labeling with [3H]tamoxifen aziridine.
Ignar-Trowbridge DM; Nelson KG; Ross KA; Washburn TF; Korach KS; McLachlan JA
J Steroid Biochem Mol Biol; 1991 Jul; 39(1):131-2. PubMed ID: 2069860
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.
Attardi B; Happe HK
Endocrinology; 1986 Aug; 119(2):904-15. PubMed ID: 3732150
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen.
Monsma FJ; Katzenellenbogen BS; Miller MA; Ziegler YS; Katzenellenbogen JA
Endocrinology; 1984 Jul; 115(1):143-53. PubMed ID: 6734512
[TBL] [Abstract][Full Text] [Related]
30. [Recognition of the activated form of estrogen receptor bound to estradiol and tamoxifen by a monoclonal antibody].
Giambiagi N; Pasqualini JR
Pathol Biol (Paris); 1986 Oct; 34(8):937-42. PubMed ID: 3537937
[TBL] [Abstract][Full Text] [Related]
31. Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo.
Nardulli AM; Katzenellenbogen BS
Endocrinology; 1986 Nov; 119(5):2038-46. PubMed ID: 3533520
[TBL] [Abstract][Full Text] [Related]
32. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
33. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
34. Amino and iodotamoxifens: synthesis, estrogen receptor affinity and biodistribution.
Strickland LA; Ponce YZ; Hunter DH; Zabel PL; Powe JE; Morrissey G; Driedger AA; Chamberlain MJ; Tustanoff ER
Drug Des Deliv; 1990 Sep; 6(3):195-212. PubMed ID: 1963782
[TBL] [Abstract][Full Text] [Related]
35. Fast action of estrogen on intracellular calcium in dormant mouse blastocyst and its possible mechanism.
Yu LL; Zhang JH; He YP; Huang P; Yue LM
Fertil Steril; 2009 Feb; 91(2):611-5. PubMed ID: 18295211
[TBL] [Abstract][Full Text] [Related]
36. The interaction site for tamoxifen aziridine with the bovine estrogen receptor.
Ratajczak T; Wilkinson SP; Brockway MJ; Hähnel R; Moritz RL; Begg GS; Simpson RJ
J Biol Chem; 1989 Aug; 264(23):13453-9. PubMed ID: 2760029
[TBL] [Abstract][Full Text] [Related]
37. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
38. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.
Boyan BD; Sylvia VL; Frambach T; Lohmann CH; Dietl J; Dean DD; Schwartz Z
Endocrinology; 2003 May; 144(5):1812-24. PubMed ID: 12697687
[TBL] [Abstract][Full Text] [Related]
39. Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm.
Devin-Leclerc J; Meng X; Delahaye F; Leclerc P; Baulieu EE; Catelli MG
Mol Endocrinol; 1998 Jun; 12(6):842-54. PubMed ID: 9626660
[TBL] [Abstract][Full Text] [Related]
40. Binding characteristics of zearalenone analogs to estrogen receptors.
Kiang DT; Kennedy BJ; Pathre SV; Mirocha CJ
Cancer Res; 1978 Nov; 38(11 Pt 1):3611-5. PubMed ID: 698923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
